Celldex Therapeutics
(NASDAQ) CLDX
Celldex Therapeutics Financials at a Glance
Market Cap
$2.61B
Revenue (TTM)
$1.50M
Net Income (TTM)
$258.80M
EPS (TTM)
$-3.90
P/E Ratio
-8.55
Dividend
$0.00
Beta (Volatility)
1.29 (Average)
Dividend
$0.00
Beta (Volatility)
1.29 (Average)
Price
$33.32
Volume
11,906
Open
$33.80
Price
$33.32
Volume
11,906
Open
$33.80
Previous Close
$33.29
Daily Range
$32.88 - $33.80
52-Week Range
$17.85 - $35.79
Dividend
$0.00
Beta (Volatility)
1.29 (Average)
Price
$33.32
Volume
11,906
Open
$33.80
Previous Close
$33.29
Daily Range
$32.88 - $33.80
52-Week Range
$17.85 - $35.79
CLDX News
CLDX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Celldex Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
198
CEO
Anthony S. Marucci, MBA
Website
www.celldex.comHeadquarters
Hampton, NJ 08827, US
CLDX Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-192%
Net Income Margin
-173%
Return on Equity
-41%
Return on Capital
-54%
Return on Assets
-44%
Earnings Yield
-11.70%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.61B
Shares Outstanding
78.46M
Volume
11.91K
Short Interest
0.00%
Avg. Volume
1.02M
Financials (TTM)
Gross Profit
$1.50M
Operating Income
$287.40M
EBITDA
$255.42M
Operating Cash Flow
$210.94M
Capital Expenditure
$2.71M
Free Cash Flow
$213.66M
Cash & ST Invst.
$518.57M
Total Debt
$2.34M
Celldex Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$75.00K
-93.6%
Gross Profit
$75.00K
-78.9%
Gross Margin
100.00%
N/A
Market Cap
$2.61B
N/A
Market Cap/Employee
$14.04M
N/A
Employees
186
N/A
Net Income
$81.36M
-72.8%
EBITDA
$80.54M
-45.9%
Quarterly Fundamentals
Net Cash
$516.24M
-28.4%
Accounts Receivable
$2.02M
+187.9%
Inventory
$0.00
N/A
Long Term Debt
$784.00K
-66.8%
Short Term Debt
$1.55M
+6.9%
Return on Assets
-44.39%
N/A
Return on Invested Capital
-54.02%
N/A
Free Cash Flow
$64.93M
-95.4%
Operating Cash Flow
$63.94M
-96.9%